Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903305 | 0.98 | CA1 (0.42) | CA1CA2CXCR4CXCL12CA12 | |
| SCHEMBL15083704 | 0.88 | CA1 (0.48) | CA1CA2CXCR4CXCL12CA12 | |
| SCHEMBL9518428 | 0.84 | CXCR4 (0.45) | CA1CA2CXCR4CXCL12CA12 | |
| SCHEMBL992810 | 0.82 | CA1 (0.40) | CA1CA2CXCR4CXCL12CA12 | |
| SCHEMBL3904234 | 0.81 | CXCR4 (0.42) | CA1CA2CXCR4CXCL12CA12 | |
| SCHEMBL21518374 | 0.81 | CXCR4 (0.46) | CA1CXCR4CXCL12CA12CA7 | |
| SCHEMBL918578 | 0.81 | CXCR4 (0.46) | CA1CXCR4CXCL12CA12CA7 | |
| SCHEMBL37872 | 0.81 | CXCR4 (0.46) | CA1CXCR4CXCL12CA12CA7 | |
| Ammonia Solution, Strong SCHEMBL4735488 | 0.79 | CXCR4 (0.45) | CA1CXCR4CXCL12CA12CA7 | |
| SCHEMBL3857080 | 0.79 | CXCR4 (0.45) | CA1CXCR4CXCL12CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| EP-2029593-A1 | INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| EP-2016068-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | claimed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | claimed |
| WO-2007129052-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-2029593-A1 | INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| EP-2016075-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016068-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007129044-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129052-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | MTOR, RPTOR, JAK2 | CA1 3671/4885CA2 1764/4885CXCR4 2408/4885 |
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | CA1 3786/4885CA2 2922/4885CXCR4 2657/4885 |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MTOR, RICTOR, PIK3R5 | CA1 4680/4885CA2 3852/4885CXCR4 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.